Phase II Trial Exploring the Feasibility of Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA Non-Small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Carboplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 21 Feb 2012 Actual end date (1 Jul 2011) added as reported by ClinicalTrials.gov.
- 21 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jan 2007 Status changed from recruiting to in progress